Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA

BMB Reports

Volumn 44, Issue 11, 2011, Pages 758-763

  Kim, Dongbum ^a   Kwon, Sanghoon ^a   Ahn, Chi Seok ^b   Lee, Younghee ^c   Choi, Soo Young ^a   Park, Jinseu ^a   Kwon, Hyeok Yil ^a   Kwon, Hyung Joo ^a  

^a Hallym University   (South Korea)

^b Motaean Women's Hospital   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

Adjuvants; CpG DNA; DCs; Lipoplex(O); PO ODN

Indexed keywords

CATION; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; CYTIDYLYL 3' 5' GUANOSINE; CYTIDYLYL-3'-5'-GUANOSINE; DINUCLEOSIDE PHOSPHATE; DNA; ESTER; HEN EGG LYSOZYME; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LIPOSOME; LYSOZYME; OLIGODEOXYRIBONUCLEOTIDE; OVALBUMIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; DENDRITIC CELL; DRUG EFFECT; IMMUNOLOGY; MALE; METABOLISM; MOUSE; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CATIONS; DENDRITIC CELLS; DINUCLEOSIDE PHOSPHATES; DNA; ESTERS; IMMUNOGLOBULIN G; INTERLEUKIN-12; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MURAMIDASE; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; TH1 CELLS;

EID: 84863270772     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2011.44.11.758     Document Type: Article

References (32)

1. Glenny, A., Pope, C., Waddington, H. and Wallace, U. (1926) The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 29, 38-45.
2. Marrack, P., McKee, A. S. and Munks, M. W. (2009) Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9, 287-293.
3. Spreafico, R., Ricciardi-Castagnoli, P. and Mortellaro, A. (2010) The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur. J. Immunol. 40, 638-642.
4. Felnerova, D., Viret, J. F., Gluck, R. and Moser, C. (2004) Liposomes and virosomes as delivery system for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 15, 518-529.
5. Simoes, S., Moreira, J. N., Fonseca, C., Duzgunes, N. and de Lima, M. C. (2004) On the formulation of pH-sensitive liposomes with long circulation times. Adv. Drug Deliv. Rev. 56, 947-965.
6. Chikh, G. and Schutze-Redelmeier, M. P. (2002) Liposomal delivery of CTL epitopes to dendritic cells. Biosci. Rep. 22, 339-353.
7. Henriksen-Lacey, M., Korsholm, K. S., Andersen, P., Perrie, Y. and Christensen, D. (2011) Liposomal vaccine delivery systems. Expert. Opin. Drug Deliv. 8, 505-519.
8. Gursel, I., Gursel, M., Ishii, K. J. and Klinman, D. M. (2001) Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 167, 3324-3328.
9. Alving, C. R., Koulchin, V., Glenn, G. M. and Rao, M. (1995) Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 145, 5-31.
10. Chang, J. S., Choi, M. J., Cheong, H. S. and Kim, K. (2001) Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. Vaccine 19, 3608-3614.
11. Brunel, F., Darbouret, A. and Ronco, J. (1999) Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Vaccine 17, 2192-2203.
12. Zheng, L., Huang, X. L., Fan, Z., Borowski, L., Wilson, C. C. and Rinaldo, C. R. Jr. (1999) Delivery of liposome- encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses. AIDS Res. Hum. Retroviruses 15, 1011-1020.
13. Klinman, D. M., Currie, D., Gursel, I. and Verthelyi, D. (2004) Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199, 201-216.
14. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V. and Harding, C. V. (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186, 1623-1631.
15. Carson, D. A. and Raz, E. (1997) Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J. Exp. Med. 186, 1621-1622.
16. Lay, M., Callejo, B., Chang, S., Hong, D. K., Lewis, D. B., Carroll, T. D., Matzinger, S., Fritts, L., Miller, C. J., Warner, J. F., Liang, L. and Fairman, J. (2009) Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 27, 3811-3820.
17. Suzuki, Y., Wakita, D., Chamoto, K., Narita, Y., Tsuji, T., Takeshima, T., Gyobu, H., Kawarada, Y., Kondo, S., Akira, S., Katoh, H., Ikeda, H. and Nishimura, T. (2004) Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 64, 8754-8760.
18. Li, W. M., Dragowska, W. H., Bally, M. B. and Schutze-Redelmeier, M. P. (2003) Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neuderived peptide co-encapsulated in liposomes. Vaccine 21, 3319-3329.
19. Choi, Y. J., Lee, K. W., Kwon, H. J. and Kim, D. S. (2006) Identification of immunostimulatory oligodeoxynucleotide from Escherichia coli genomic DNA. J. Biochem. Mol. Biol. 39, 788-793.
20. Lee, K. W., Jung, J., Lee, Y., Kim, T. Y., Choi, S. Y., Park, J., Kim, D. S. and Kwon, H. J. (2006) Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol. Immunol. 43, 2107-2118.
21. Kim, D., Rhee, J. W., Kwon, S., Sohn, W. J., Lee, Y., Kim, D. W., Kim, D. S. and Kwon, H. J. (2009) Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA. Biochem. Biophys. Res. Commun. 379, 362-367.
22. Kim, D., Kwon, S., Rhee, J. W., Kim, K. D., Kim, Y. E, Park C. S., Choi, M. J., Suh, J. G., Kim, D. S., Lee, Y. and Kwon, H. J. (2011) Production of antibodies with peptide-CpGDNA-liposome complex without carriers. BMC Immunol. 12, 29.
23. Ben-Yedidia, T and Arnon, R. (1997) Design of peptide and polypeptide vaccines. Curr. Opin. Biotechnol. 8, 442-448.
24. Bijker, M. S., Melief, C. J., Offringa, R. and van der Burg, S. H. (2007) Design and development of synthetic peptide vaccines: past, present and future. Expert Rev. Vaccines 6, 591-603.
25. Castilow, E. M., Olson, M. R. and Varga, S. M. (2007) Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol. Res. 39, 225-239.
26. Reed, S. G., Bertholet, S., Coler, R. N. and Friede, M. (2009) New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23-32.
27. Lipford, G. B., Sparwasser, T., Zimmermann, S., Heeg, K. and Wagner, H. (2000) CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J. Immunol. 165, 1228-1235.
28. Heikenwalder, M., Polymenidou, M., Junt, T., Sigurdson, C., Wagner, H., Akira, S., Zinkernagel, R. and Aguzzi, A. (2004) Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10, 187-192.
29. Deng, G. M., Nilsson, I. M., Verdrengh, M., Collins, L. V. and Tarkowski, A. (1999) Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat. Med. 5, 702-705.
30. Gregoriadis, G., Saffie, R. and Hart, S. L. (1996) High yield incorporation of plasmid DNA within liposomes: Effect on DNA integrity and transfection efficiency. J. Drug Target. 3, 469-475.
31. Lutz, M. B., Schnare, M., Menges, M., Rössner, S., Röllinghoff, M., Schuler, G. and Gessner, A. (2002) Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J. Immunol. 169, 3574-3580.
32. Kim, D., Jung, J., Lee, Y. and Kwon, H. J. (2011) Novel immunostimulatory phosphodiester oligodeoxynucleotides with CpT sequences instead of CpG motifs. Mol. Immunol. 48, 1494-1504.